What is SciFluor Life Sciences?
SciFluor Life Sciences is dedicated to creating proprietary, best-in-class drugs targeting significant medical needs across ophthalmology, neuroscience, and fibrotic diseases. The company leverages well-understood biological pathways to develop its therapeutic candidates. Its lead clinical drug, SF0166, is an eye drop formulation designed for the treatment of back-of-the-eye diseases, representing a key focus in its development pipeline.
How much funding has SciFluor Life Sciences raised?
SciFluor Life Sciences has raised a total of $44.6M across 2 funding rounds:
Series A
$30M
Series B
$14.6M
Series A (2015): $30M with participation from Woodford Investment Management and Allied Minds
Series B (2021): $14.6M, investors not publicly disclosed
Key Investors in SciFluor Life Sciences
Woodford Investment Management
Woodford Investment Management is a financial services firm known for managing various investment funds. The firm has been involved in managing investment portfolios, and its clients typically seek managed investment solutions. The company operates under UK financial regulations.
Allied Minds
Allied Minds is a U.S.-based science and technology development company that forms, funds, and manages businesses based on innovative technologies from leading research institutions. It functions as a diversified holding company providing capital and management support.
What's next for SciFluor Life Sciences?
The recent major enterprise-level funding and strategic investment indicate SciFluor Life Sciences is poised for significant scaling and advancement of its drug development programs. This capital infusion will likely accelerate clinical trials, expand research and development efforts, and potentially support the commercialization strategy for its lead candidate, SF0166. The company's focus on areas with substantial unmet medical needs positions it for substantial growth and impact in the pharmaceutical sector.
See full SciFluor Life Sciences company page
